Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Observational 1Interventional 1

Sponsor

Cancer Type

Gastrointestinal 3Breast 2Gynecologic 1

Conditions

Breast Neoplasms 6392Neoplasms 408Ovarian Neoplasms 308Triple Negative Breast Neoplasms 286Prostatic Neoplasms 280Lung Neoplasms 271Colorectal Neoplasms 255Neoplasm Metastasis 254Carcinoma, Non-Small-Cell Lung 221Breast Neoplasms, Male 201Colonic Neoplasms 168Motor Activity 166Pancreatic Neoplasms 164Melanoma 157Carcinoma, Intraductal, Noninfiltrating 139Stomach Neoplasms 128Uterine Cervical Neoplasms 127Head and Neck Neoplasms 124Fatigue 104Breast Carcinoma In Situ 103Carcinoma, Ovarian Epithelial 98Endometrial Neoplasms 96Lymphedema 95Carcinoma, Renal Cell 94Urinary Bladder Neoplasms 93Pain 90Sarcoma 89Small Cell Lung Carcinoma 85Lymphoma 83Esophageal Neoplasms 81

Interventions

2,2'-dithiodiethanesulfonic acid 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × Paresthesia × Breast × Clear all
NCT00039780 2022-07-13

Evaluation of BNP7787 for the Prevention of Neurotoxicity in Metastatic Breast Cancer Patients Receiving Weekly Paclitaxel

BioNumerik Pharmaceuticals, Inc.

Phase 3 Completed
764 enrolled
Breast

Breast Diseases, Breast Neoplasms, Neoplasm Metastasis, Neoplasms, Paresthesia, Neurotoxicity Syndromes

NCT00746694 2015-08-27

A Study to Determine the Management of Palmar-plantar Erythrodysesthesia (PPE) in Patients With Metastatic Ovarian or Breast Cancer Treated With Caelyx (Study P05020)

Merck Sharp & Dohme LLC

Completed
154 enrolled 7 charts
BreastGynecologic

Breast Neoplasms, Ovarian Neoplasms, Paresthesia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡